These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 31300829)
1. Estimating the optimal dose of flupentixol decanoate in the maintenance treatment of schizophrenia-a systematic review of the literature. Bailey L; Taylor D Psychopharmacology (Berl); 2019 Nov; 236(11):3081-3092. PubMed ID: 31300829 [TBL] [Abstract][Full Text] [Related]
2. Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders. Mahapatra J; Quraishi SN; David A; Sampson S; Adams CE Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD001470. PubMed ID: 24915451 [TBL] [Abstract][Full Text] [Related]
3. Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Serum levels at the minimum effective dose. Kistrup K; Gerlach J; Aaes-Jørgensen T; Larsen NE Psychopharmacology (Berl); 1991; 105(1):42-8. PubMed ID: 1745710 [TBL] [Abstract][Full Text] [Related]
4. Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders. Quraishi S; David A Cochrane Database Syst Rev; 2000; (2):CD001470. PubMed ID: 10796442 [TBL] [Abstract][Full Text] [Related]
5. Steady-state serum concentrations after cis (Z)-flupentixol decanoate in viscoleo. Saikia JK; Jørgensen A Psychopharmacology (Berl); 1983; 80(4):371-3. PubMed ID: 6414008 [TBL] [Abstract][Full Text] [Related]
6. [Incidence of rigor during treatment with flupentixol decanoate in comparison to risperidone]. Scherer J; Dobmeier P; Kuhn K; Schmaus W Psychiatr Prax; 2004 Nov; 31 Suppl 1():S167-9. PubMed ID: 15570542 [TBL] [Abstract][Full Text] [Related]
7. Comparison of serum levels after intramuscular injections of 2% and 10% cis(Z)-flupentixol decanoate in Viscoleo to schizophrenic patients. Stauning JA; Kirk L; Jøorgensen A Psychopharmacology (Berl); 1979 Sep; 65(1):69-72. PubMed ID: 116292 [TBL] [Abstract][Full Text] [Related]
8. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation]. Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I Encephale; 2005; 31(2):235-46. PubMed ID: 15959450 [TBL] [Abstract][Full Text] [Related]
9. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Turner M; Eerdekens E; Jacko M; Eerdekens M Int Clin Psychopharmacol; 2004 Jul; 19(4):241-9. PubMed ID: 15201572 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data. Frey S; Linder R; Juckel G; Stargardt T Eur J Health Econ; 2014 Mar; 15(2):133-42. PubMed ID: 23420082 [TBL] [Abstract][Full Text] [Related]
11. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020. Yıldız M; Osman E Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516 [TBL] [Abstract][Full Text] [Related]
12. Serum concentrations of cis(Z)-flupentixol and prolactin in chronic schizophrenic patients treated with flupentixol and cis(Z)-flupentixol decanoate. Jørgensen A; Andersen J; Bjørndal N; Dencker SJ; Lundin L; Malm U Psychopharmacology (Berl); 1982; 77(1):58-65. PubMed ID: 6812119 [TBL] [Abstract][Full Text] [Related]
13. Haloperidol decanoate and flupenthixol decanoate in schizophrenia. A long-term double-blind cross-over comparison. Eberhard G; Hellbom E Acta Psychiatr Scand; 1986 Sep; 74(3):255-62. PubMed ID: 3788652 [TBL] [Abstract][Full Text] [Related]
14. Long-term treatment with flupentixol results of a post-marketing surveillance study. Messer T; Glaser T; Landen H; Schmauss M J Psychopharmacol; 2009 Sep; 23(7):805-13. PubMed ID: 18562418 [TBL] [Abstract][Full Text] [Related]
15. Flupentixol and flupentixol decanoate, with special reference to their antipsychotic effect. Gottfries CG Acta Psychiatr Belg; 1974 Sep; 74(5):507-16. PubMed ID: 4620362 [No Abstract] [Full Text] [Related]
16. Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms. Ruhrmann S; Kissling W; Lesch OM; Schmauss M; Seemann U; Philipp M Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1012-22. PubMed ID: 17412473 [TBL] [Abstract][Full Text] [Related]
17. [Intervals between hospitalisations in schizophrenia patients under antipsychotics in depot-form versus oral second generation antipsychotics]. Gutwinski S; Müller P; Koller M Psychiatr Prax; 2007 Sep; 34(6):289-91. PubMed ID: 17806015 [TBL] [Abstract][Full Text] [Related]
18. Brain volume changes over the first year of treatment in schizophrenia: relationships to antipsychotic treatment. Emsley R; Asmal L; du Plessis S; Chiliza B; Phahladira L; Kilian S Psychol Med; 2017 Sep; 47(12):2187-2196. PubMed ID: 28347393 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. McEvoy JP; Byerly M; Hamer RM; Dominik R; Swartz MS; Rosenheck RA; Ray N; Lamberti JS; Buckley PF; Wilkins TM; Stroup TS JAMA; 2014 May; 311(19):1978-87. PubMed ID: 24846035 [TBL] [Abstract][Full Text] [Related]
20. Flupenthixol decanoate and injection site abscesses in an obese patient. Andrade C Aust N Z J Psychiatry; 2002 Aug; 36(4):561-2. PubMed ID: 12169162 [No Abstract] [Full Text] [Related] [Next] [New Search]